Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA. Lindner LH, et al. Among authors: marreaud s. Int J Cancer. 2018 Jun 15;142(12):2610-2620. doi: 10.1002/ijc.31286. Epub 2018 Feb 14. Int J Cancer. 2018. PMID: 29383713 Free PMC article.
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS, Reichardt P, Christensen TB, Pink D, Daugaard S, Hermans C, Marreaud S, van Glabbeke M, Blay J, Judson I. Nielsen OS, et al. Among authors: marreaud s. Eur J Cancer. 2006 Sep;42(14):2303-9. doi: 10.1016/j.ejca.2006.04.011. Epub 2006 Aug 7. Eur J Cancer. 2006. PMID: 16891112 Clinical Trial.
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Reichardt P, Nielsen OS, Bauer S, Hartmann JT, Schöffski P, Christensen TB, Pink D, Daugaard S, Marreaud S, Van Glabbeke M, Blay JY; EORTC Soft Tissue and Bone Sarcoma Group. Reichardt P, et al. Among authors: marreaud s. Eur J Cancer. 2007 Apr;43(6):1017-22. doi: 10.1016/j.ejca.2007.01.014. Epub 2007 Mar 1. Eur J Cancer. 2007. PMID: 17336054 Clinical Trial.
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY. Sleijfer S, et al. Among authors: marreaud s. J Clin Oncol. 2009 Jul 1;27(19):3126-32. doi: 10.1200/JCO.2008.21.3223. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451427 Clinical Trial.
Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).
van Laarhoven HW, Fiedler W, Desar IM, van Asten JJ, Marréaud S, Lacombe D, Govaerts AS, Bogaerts J, Lasch P, Timmer-Bonte JN, Lambiase A, Bordignon C, Punt CJ, Heerschap A, van Herpen CM. van Laarhoven HW, et al. Among authors: marreaud s. Clin Cancer Res. 2010 Feb 15;16(4):1315-23. doi: 10.1158/1078-0432.CCR-09-1621. Epub 2010 Feb 9. Clin Cancer Res. 2010. PMID: 20145168 Free article. Clinical Trial.
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients.
Desar IM, van Herpen CM, van Asten JJ, Fiedler W, Marreaud S, Timmer-Bonte JN, ter Voert EG, Lambiase A, Bordignon C, Heerschap A, van Laarhoven HW. Desar IM, et al. Among authors: marreaud s. Eur J Radiol. 2011 Dec;80(3):655-61. doi: 10.1016/j.ejrad.2010.08.045. Epub 2010 Sep 21. Eur J Radiol. 2011. PMID: 20863638
Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study.
Penel N, Glabbeke MV, Mathoulin-Pelissier S, Judson I, Sleijfer S, Bui B, Schoffski P, Ouali M, Marreaud S, Brouste V, Duhamel A, Hohenberger P, Blay JY. Penel N, et al. Among authors: marreaud s. Br J Cancer. 2011 May 10;104(10):1544-50. doi: 10.1038/bjc.2011.136. Epub 2011 Apr 19. Br J Cancer. 2011. PMID: 21505457 Free PMC article.
114 results